References
- Pistiner M, Wallace DJ, Nessim S, Metzger AL, Klineberg JR. Lupus erythematosus in the 1980s: a survey of 570 patients. Semin Arthritis Rheum 1991;21: 55–64.
- Illei GG, Austin HA, Crone M, Collins L, Gourley MF, Yorboro CH, et al. Combination therapy with pulse cyclophosphamide plus pulse methylprednisolone improves long-term renal outcome with-out adding toxicity in patients with lupus nephritis. Ann Intern Med 2001;135:248–57.
- Yoshioka K, Ohashi K, Sakai T, Ito H, Yoshikawa N, Nakamura H, et al. A multicenter trial of mizoribine compared with placebo in children with frequently relapsing nephrotic syndrome. Kidney Int 2000;58:317–24.
- Cacccavo D, Lagana B, Mitterhofer AP, Ferri GM, Afeltra A, Amoroso A, et al. Long-term treatment of systemic lupus erythe-matosus with cyclosporine A. Arthritis Rheum 1997;40:27–35.
- Kingdon EJ, Mclean AG, Psimenou E, Davenport A, Powis SH, Sweny P, et al. The safety and efficacy of MMF in lupus nephritis: a pilot study. Lupus 2001;10:606–11.
- Mitchell BS, Dayton JS, Turka LA, Thompson CB. IMP dehydro-genase inhibitors as immunomodulators. Ann N Y Acad Sci 1993;685:217–24.
- Aihara Y, Miyamae T, Ito S, Kobayashi S, Imagawa T, Mori M, et al. Mizoribine as an effective combined maintenance therapy with prednisolone in child-onset systemic lupus erythematosus. Pediatr Int 2002;44:199–204.
- Yoshidome K, Takei S, Imanaka H, Maeno N, Ohkawa T, Kawano Y. Efficacy of mizoribine in the treatment of systemic lupus erythe-matosus in children. Pediatr Int 2004;46:444–9.
- Tanaka H, Abe T, Nishimura S, Sakai H, Kimura H, Oki M, et al. A case of rheumatoid arthritis/Sjogren's syndrome with acute renal failure due to hyperuricemia associated with mizoribine therapy. Jpn J Clin Immunol 2004;27:171–6.
- Shibasaki T, Koyama A, Hishida A, Muso E, Osawa G, Yamabe H, et al. A randomized open-label comparative study of conventional therapy versus mizoribine only therapy in patients with steroid-resistant nephrotic syndrome (postmarketing survey). Clin Exp Nephrol 2004;8:117–26.
- Bstuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Walkenstein P. SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 2000;115:149–53.
- Prins C, Vittorio C, Padilla RS, Hunziker T, Itin P, Forster J, et al. Effect of high-dose intravenous immunoglobulin therapy in Stevens-Johnson syndrome: a retrospective, multicenter study. Dermatology 2003;207:96–9.
- Mori H, Yamanaka K, Kaketa M, Tamada K, Hakamada A, Isoda K, et al. Drug eruption caused by azathioprine: value of using the drug-induced lymphocytes stimulation test for diagnosis. J Dermatol 2004; 31:731–6.
- Wolf R, Matz H, Macros B, Orion E. Drug rash with eosinophilia and systemic symptoms vs toxic epidermal necrosis: the dilemma of classification. Clin Dermatol 2005;23: 311–4.
- Hinchey J, Chaves C, Appignani B, Breen J, Pao L, Wang A, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med 1996;334:494–500.